Three Independent Analyst Reports Give Nymox ''Buy'' Recommendations; Nymox (NASDAQ: NYMX) Rated ''Speculative Buy'' by Wallstreet Research, ''Strong Speculative Buy'' by Dutton Associates, and ''Buy'' by Cohen Independent Research Group.

HASBROUCK HEIGHTS, N.J. -- Three current independent analyst reports have "buy" recommendations for Nymox Pharmaceutical Corporation (NASDAQ: NYMX). These include: Wallstreet Research (written by Alan Stone on July 17, 2006), Dutton Associates (written by Dr. William Prather on June 6, 2006), and Cohen Independent Research Group (written on May 5, 2006).

The Dutton report states, "We are maintaining our 12-month price target on the common shares of $6.25 and our rating of Strong Speculative Buy. We believe NX -1207 is on track. On January 23, 2006, the Company announced that an Independent Data Monitoring Committee has given a positive recommendation for NX-1207 based on evaluation of the data in the Company's current pivotal Phase 2 trial. The Independent Data Monitoring Committee is an arm's length independent body, which has examined unblinded trial results and reached a favorable conclusion, and has recommended continuation of the trial. Additionally, on February 23, 2006, Nymox announced that their latest internal review of the current available safety data for its ongoing multi-center Phase 2 trial of NX-1207 has revealed no serious drug side effects."

The Wallstreet Research report writes, "Nymox is a diversified biopharmaceutical research and development company with an extensive portfolio of patented technologies for proprietary diagnostic and therapeutic products targeting primarily the unmet medical needs of the aging population. In the recent months, the Company has put a major emphasis on finalizing multi-center Phase II clinical studies of an advanced drug candidate for the treatment of benign prostatic hyperplasia (BPH), an enlarged prostate condition highly prevalent among elderly men." The report states "having achieved significant milestones and moving clinical trials of its product-rich portfolio ahead into more significant phases in the past several years, the Company has recently attracted some attention in the marketplace, but still appears undervalued. Its numerous projects allow for diversification of business risk and often result in other synergistic product development benefits. With no long-term debt and a low burn rate comparing to industry standards, especially considering the number of marketed products and significant projects in the pipeline, the Company appears to be an excellent buying opportunity."

According to the Cohen Independent Research Group, "We reiterate our BUY rating for Nymox Pharmaceutical Corporation, with a base target price of $7.20. Our optimism is based on the potential of the Company's NX-1207 treatment for Benign Prostate Hyperplasia (BPH) to become the best-selling drug on the market for this condition. Nymox's BPH compound is on schedule to enter Phase III clinical trials in late 2006. The Company is also looking to secure marketing collaborations for NX-1207, which would provide further impetus to the stock. Additionally, Nymox's currently available diagnostic products - AlzheimAlert(TM), NicAlert(TM) and TobacAlert(TM) - continue to provide cash flows for the development of other therapeutic products, including NX-1207 and NXC-4720, its treatment for E. coli O157 contamination."

More information about Nymox is available at www.nymox.com, email: [e-mail], or 800-936-9669.

The above analyst reports contain disclaimers stated in each individual report, and also stated in Nymox's initial press releases on the issuance of the reports, which concern risks, uncertainties, and limitations of the reports. This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities.